Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/10/21
Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/10/21
Earnings Preview: Clearside Biomedical, Inc. (CLSD) Q4 Earnings Expected to DeclineZacks Investment Research • 03/03/21
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMDGlobeNewsWire • 03/02/21
Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021GlobeNewsWire • 02/24/21
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021GlobeNewsWire • 02/23/21
Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 ProgramGlobeNewsWire • 02/16/21
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society MeetingGlobeNewsWire • 02/08/21
Clearside Biomedical's (CLSD) Shares March Higher, Can It Continue?Zacks Investment Research • 02/02/21
Implied Volatility Surging for Clearside Biomedical (CLSD) Stock OptionsZacks Investment Research • 01/14/21
Are You Looking for a Top Momentum Pick? Why Clearside Biomedical, Inc. (CLSD) is a Great ChoiceZacks Investment Research • 01/13/21
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMDGlobeNewsWire • 01/12/21
Clearside Biomedical Announces Pricing of $12 Million Registered Direct OfferingGlobeNewsWire • 01/06/21
Week 1 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 01/02/21
Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and TechnologyGlobeNewsWire • 11/16/20
Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewsWire • 11/11/20
Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/11/20
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/20
Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020GlobeNewsWire • 10/30/20
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology RetinaGlobeNewsWire • 09/23/20
Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal DeliveryGlobeNewsWire • 09/11/20